Shots: The EC approval is based on a P-III QUAZAR AML-001 study assessing Onureg (300mg, qd) vs PBO + BSC for 14days of a 28-day cycle in patients aged ≥55yrs. […]readmore
Tags : QUAZAR AML-001
Shots: The P-III QUAZAR AML-001 study involves assessing of CC-486 (300mg) as maintenance therapy vs PBO + SoC in 472 patients in a ratio (1:1) with AML who achieved first […]readmore